A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
about
New molecular targets in mantle cell lymphomaDynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironmentMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsA phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas.Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.Do mantle cell lymphomas have an 'Achilles heel'?Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisB-cell receptor signaling as a driver of lymphoma development and evolution.Molecular targeted approaches in mantle cell lymphoma.Novel targeted therapies for mantle cell lymphomaMolecular pathogenesis of mantle cell lymphoma.The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trialCurrent approaches and advance in mantle cell lymphoma treatment.Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.Current and emerging new treatment strategies for mantle cell lymphoma.Everolimus in colorectal cancer.Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.Management of mantle cell lymphoma in the elderly: current and potential strategies.The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.Current regimens and novel agents for mantle cell lymphoma.New therapies in non-Hodgkin lymphoma.Are we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma?Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI.Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.How to manage mantle cell lymphoma.Novel therapies for aggressive B-cell lymphomaMantle cell lymphoma: taking therapeutic advantage of new insights into the biology.Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers.Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly
P2860
Q26821766-D28D0EBE-2E29-4074-80FC-3CDE655C3535Q27025321-94D37D95-47CF-40D5-8D4A-1DC022CC946BQ28075606-A9054CF3-9E4F-4886-ADB9-0E7F4E8C6263Q33409982-CF9CE361-5D9E-4499-97A2-3829360273CDQ33410761-AE256EB6-64EB-4CF8-95A8-855094FD1A07Q33413598-CD7FEBEA-3BFA-43E2-80E8-FCD3BAFBC2EBQ33414243-1A03E937-9216-4B6D-ACA4-070ABD10D659Q33421147-8B955179-11F7-4B3E-8511-1E1DC77F8235Q33429898-0391ECCE-2608-40FE-B85D-FA322DF336D8Q34090009-DC337D0D-2B69-4ED3-A5CE-FD089F2FFBF6Q34272887-50AD232C-D4E5-44E0-BABB-28C42AD12945Q34398579-B8580986-1D6D-46FF-AC0D-A2CEDE5EBC76Q35127368-E60C97F2-459B-42B6-9DE8-B7219D99D6D8Q35889841-3F5C209D-6F68-4566-8CDC-D848D9DEACA7Q36290246-88B51159-359E-483A-AC14-F906ED439435Q36734547-F9ACD1D1-B362-4C01-9E1F-6AC9BC2D1BA4Q37044078-496A4792-8294-4A7C-A755-26E18310FC57Q37613320-05CD0DFE-F317-415B-8B55-EA79916C173CQ38056761-51ED13DF-2795-41D9-9E08-E5C5A30168A6Q38081233-FD36A47E-E03E-464D-A5B7-2725BFE256BFQ38122437-23E75387-8682-4672-B558-E847A330E566Q38157682-1BAB2E5F-3A46-48BE-A8BD-3E348E657458Q38195885-D5C6F68F-2245-4BC7-BAFF-12CACAA3593EQ38212951-D970F9BF-F6EF-4C53-BDCE-42A8389819B5Q38222824-081B6176-5AEC-4575-BEAB-7BBD56943A6CQ38224186-5436C7FC-ED57-4EB9-9B49-531D99B2C561Q38315779-5974693A-B327-4BF0-9675-E91F268CE3CCQ38382492-0791FE69-ADFD-4F64-B77B-DB8D264BE548Q38675161-F64898CC-B4D9-4B47-B693-34930555E04AQ38773520-D133C40B-BDB9-4B49-852B-2D31109C0146Q38957093-E893863C-D5C0-4A29-8111-233EB922F706Q39187610-A7EBBE82-75B2-4CCB-99C9-685F54B54769Q42011578-40A694C3-1546-460D-8A29-32898715F5A7Q44679554-3C243B53-8B78-45AA-B26A-C676580576C9Q45253711-4763AE08-64D8-42E3-86C4-43DE4D91BFB2Q46909057-27CCD924-5635-4731-8A36-1350C1334A47Q47804413-A1C90D00-D529-41B9-BF13-7C737C199421Q51272851-F337DE82-C976-4E5E-BDBF-0126D1E116C9Q51832606-3D4FBACF-8D73-4723-9EBB-315CCF8EDF77Q54316519-CD649A19-94DB-4D73-98BC-E1450109BC56
P2860
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A multicenter phase II trial ( ...... fractory mantle cell lymphoma.
@ast
A multicenter phase II trial ( ...... fractory mantle cell lymphoma.
@en
type
label
A multicenter phase II trial ( ...... fractory mantle cell lymphoma.
@ast
A multicenter phase II trial ( ...... fractory mantle cell lymphoma.
@en
prefLabel
A multicenter phase II trial ( ...... fractory mantle cell lymphoma.
@ast
A multicenter phase II trial ( ...... fractory mantle cell lymphoma.
@en
P2093
P2860
P50
P1433
P1476
A multicenter phase II trial ( ...... fractory mantle cell lymphoma.
@en
P2093
Andreas Lohri
Andreas Trojan
Christine Biaggi
Christoph Renner
Felicitas Hitz
Krimo Bouabdallah
Mario Bargetzi
Michele Ghielmini
Nicolas Ketterer
Peter Brauchli
P2860
P304
P356
10.3324/HAEMATOL.2011.053173
P577
2012-02-07T00:00:00Z